Despite past setbacks, Sony Pictures remains committed to making a Sinister Six film, originally planned during ‘The Amazing Spider-Man’ era. Drew Goddard, known for ‘Cabin in the Woods,’ once wrote a ...

The tech experts at Digital Trends explain how to cast an iPhone screen to Sony TVs for easy media sharing. What is attendance like at Trump's state fair? Here's what we found. Iranian clerics call ...

In a recent interview on “The Town” podcast, Sony Pictures CEO Tom Rothman addressed rumors that the studio’s Spider-Man spin-off universe was finished after a string of box office failures. That ...

Dialog sounds clear and detailed. Provides an impressive bass response. The balance between the subwoofer and bar is seamless. Virtual surround sound is solid, and the setup and usability is ...

Italy’s Angelini Pharma has acquired Florida-based rare disease specialist Catalyst and its potential blockbuster Firdapse for $4.1 billion. (AndreyPopov/iStock ...

Rare-disease specialist Catalyst Pharmaceuticals is set to be acquired by healthcare group Angelini Pharma in a $4.1 billion deal. Angelini will pay $31.50 for each of Nasdaq-listed Catalyst’s ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. The Italian company Angelini Pharma ...

State-backed CDP Equity to have a stake in combined entity Deal comes after Chiesi's $1.9 billion buyout of U.S. KalVista Angelini aims to create global player in rare disease drugs ROME/MILAN, May 7 ...

Sony, owner of the PlayStation brand, has been accused of antitrust practices. The lawsuit was originally settled in 2024 but was rejected twice during the approval process. Last week, a judge ...

Clint Henderson is a managing editor at TPG who has worked in the journalism industry for more than 25 years. He is obsessed with travel and has used points and miles to explore the world. The cards ...

Italian drugmaker Angelini Pharma is exploring a potential acquisition of Catalyst Pharmaceuticals Inc. as it looks at deals to expand its footprint globally, people familiar with the matter said.